PURPOSE: A flow diverter (FD) is an effective treatment option for intracranial aneurysms. The Flow Re-direction Endoluminal Device (FRED) is a relatively new flow diverter with a unique dual-layer design. We report our experience and short-term results with the FRED. MATERIALS AND METHODS: We did a retrospective review of all consecutive cases in which the FRED was used to treat intracranial aneurysms at a single institution from March 2014 till December 2015. Clinical parameters, aneurysm characteristics, technical results and short-term outcomes were reviewed. RESULTS: Eleven intracranial aneurysms were treated with the FRED in 11 patients. The technical device deployment success rate was 100%. Immediate reduction in intra-aneurysmal flow after deployment was noted in 10 cases. The aneurysm occlusion rate at 6 months was 75%. There was 1 complication of in-stent thrombosis immediately after deployment. There was no side branch occlusion, delayed aneurysm rupture, stroke, or intraparenchymal haemorrhage. There was no neurological deficit, morbidity, or mortality. CONCLUSION: The FRED is a new FD. It has shown to be safe and effective in our series. The unique dual-layer design of the device renders it to have technical advantages over other FDs. The 6-month aneurysm occlusion rate and complication profile of FRED are similar to other FDs.
PURPOSE: A flow diverter (FD) is an effective treatment option for intracranial aneurysms. The Flow Re-direction Endoluminal Device (FRED) is a relatively new flow diverter with a unique dual-layer design. We report our experience and short-term results with the FRED. MATERIALS AND METHODS: We did a retrospective review of all consecutive cases in which the FRED was used to treat intracranial aneurysms at a single institution from March 2014 till December 2015. Clinical parameters, aneurysm characteristics, technical results and short-term outcomes were reviewed. RESULTS: Eleven intracranial aneurysms were treated with the FRED in 11 patients. The technical device deployment success rate was 100%. Immediate reduction in intra-aneurysmal flow after deployment was noted in 10 cases. The aneurysm occlusion rate at 6 months was 75%. There was 1 complication of in-stent thrombosis immediately after deployment. There was no side branch occlusion, delayed aneurysm rupture, stroke, or intraparenchymal haemorrhage. There was no neurological deficit, morbidity, or mortality. CONCLUSION: The FRED is a new FD. It has shown to be safe and effective in our series. The unique dual-layer design of the device renders it to have technical advantages over other FDs. The 6-month aneurysm occlusion rate and complication profile of FRED are similar to other FDs.
Authors: I Szikora; Z Berentei; Z Kulcsar; M Marosfoi; Z S Vajda; W Lee; A Berez; P K Nelson Journal: AJNR Am J Neuroradiol Date: 2010-02-11 Impact factor: 3.825
Authors: Lee A Tan; Kiffon M Keigher; Stephan A Munich; Roham Moftakhar; Demetrius K Lopes Journal: J Neurointerv Surg Date: 2014-02-19 Impact factor: 5.836
Authors: Josser E Delgado Almandoz; Benjamin M Crandall; Jill M Scholz; Jennifer L Fease; Ruth E Anderson; Yasha Kadkhodayan; David E Tubman Journal: J Neurointerv Surg Date: 2013-01-12 Impact factor: 5.836
Authors: Mario Zanaty; Nohra Chalouhi; Stavropoula I Tjoumakaris; Robert H Rosenwasser; L Fernando Gonzalez; Pascal Jabbour Journal: Front Neurol Date: 2014-02-28 Impact factor: 4.003
Authors: Muhammad Waqas; Rimal H Dossani; Modhi Alkhaldi; Jocelyn Neveu; Justin M Cappuzzo; Jaims Lim; Asham Khan; Victoria Lazarov; Andre Monteiro; Jason M Davies; Adnan H Siddiqui; Elad I Levy Journal: Interv Neuroradiol Date: 2021-06-30 Impact factor: 1.764